Lyka Labs reports promoter group acquisition increasing stake to 16.19%

What Lyka Labs announced

Lyka Labs Ltd (BSE: 500259, NSE: LYKALABS) filed a disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on 29 June 2026. The filing informs the market that the company’s promoter group, led by Mr Kunal Gandhi, has increased its shareholding in the firm through open‑market purchases.

"For and on behalf of Promoter & Promoters Group Lyka Labs Limited, Kunal N. Gandhi, Mumbai, 26th June, 2026."

The disclosure details the number of shares held before and after the transaction, the parties involved, and confirms that the acquisition did not involve any issuance of new shares.

Details of the share acquisition

The promoter group consists of Mr Kunal Gandhi, Mrs Nehal N. Gandhi, Mrs Alisha K. Gandhi, Enai Trading and Investment Private Limited, and two persons acting in concert – Lyka Generics Limited and Hiralaxmi Multitrade Pvt Ltd. Prior to the acquisition, their combined holding was 5,721,708 shares, representing 16.03 % of Lyka Labs’ total voting capital.

On 24 June 2026 and 25 June 2026, the group acquired an additional 55,967 shares (0.15 % of the total). The post‑acquisition holding rose to 5,777,675 shares, or 16.19 % of the company’s equity. The breakdown of the new holdings is as follows:

• Mrs Nehal N. Gandhi: 11,95,493 shares (3.35 %)
• Mr Kunal N. Gandhi: 35,00,162 shares (9.81 %)
• Mrs Alisha K. Gandhi: 50,000 shares (0.14 %)
• Enai Trading and Investment Pvt Ltd: 10,11,312 shares (2.83 %)
• Lyka Generics Ltd: 20,000 shares (0.06 %)
• Hiralaxmi Multitrade Pvt Ltd: 708 shares (0.00 %)

The mode of acquisition is stated as Open Market, meaning the shares were bought from existing shareholders on the stock exchanges rather than through a preferential allotment, rights issue, or any other capital‑raising mechanism.

Key facts at a glance

Why this matters for investors

The increase in promoter shareholding signals a continued confidence by the controlling group in Lyka Labs’ future prospects. Because the acquisition was executed on the open market, there is no dilution of existing shareholders; the total number of equity shares remains unchanged at 3.56 crore. The filing also satisfies SEBI’s requirement for timely disclosure when a promoter’s stake crosses certain thresholds, ensuring transparency for market participants.

For investors, the key implications are:

• Ownership concentration: The promoter group now controls a slightly larger slice of voting power (16.19 % vs 16.03 %). While still below a controlling majority, any further accumulation could influence board composition and strategic decisions.
• Liquidity impact: Open‑market purchases remove shares from the free‑float, potentially affecting short‑term liquidity but not the overall capital structure.
• Regulatory compliance: The filing confirms that the promoter group is adhering to SEBI’s Substantial Acquisition of Shares & Takeovers (SAST) regulations, reducing regulatory risk.

No encumbrances, pledges, or convertible instruments were reported in connection with the acquired shares, indicating that the promoter’s stake is unencumbered and fully exercisable.

Conclusion

Lyka Labs’ regulator‑mandated disclosure shows that its promoter group has modestly increased its equity stake to 16.19 % through open‑market purchases on 24‑25 June 2026. The transaction does not alter the company’s share capital, nor does it introduce any new securities. While the increase is modest, it reinforces the promoter’s commitment to the business and fulfills SEBI’s disclosure obligations. Future filings will reveal whether the promoter group continues to build its position.

FAQs

1. Who are the acquirers and what is their relationship to Lyka Labs? The acquirers are Mr Kunal Gandhi, Mrs Nehal N. Gandhi, Mrs Alisha K. Gandhi, Enai Trading and Investment Private Limited, and two persons acting in concert – Lyka Generics Limited and Hiralaxmi Multitrade Pvt Ltd. They belong to the promoter group of Lyka Labs, as confirmed in the filing.

2. How many shares were acquired and what is the new holding percentage? The promoter group bought 55,967 additional shares, raising its total holding to 5,777,675 shares, which equals 16.19 % of Lyka Labs’ total equity share capital.

3. Was the acquisition done through a public issue or open market? The filing states the mode of acquisition as Open Market, meaning the shares were purchased from existing shareholders on the stock exchanges.

4. Does the transaction affect the total number of shares outstanding? No. The total equity share capital of Lyka Labs remains unchanged at 3,56,90,000 shares; the transaction involved only a transfer of existing shares.

5. Are there any pledges or encumbrances on the acquired shares? The disclosure reports NIL for shares in the nature of encumbrance, pledges, liens, or non‑disposal undertakings, indicating the acquired shares are unencumbered.

6. What regulatory requirement triggered this filing? The disclosure is made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, which mandates reporting when promoters acquire additional shares that could affect control.